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ABSTRACT
This study examined the ability of a pre-recorded videoconferencing (VC) audience to
elicit the physiological and subjective arousal associated with Social Anxiety Disorder (SAD)
when giving a formal presentation. This study had three objectives: (a) to determine whether
speaking to the VC audience elicited significant increases in physiological response (e.g., heart
rate and electrodermal activity) and subjective distress over baseline resting conditions (b) to
determine whether the VC task more closely replicates the physiological and subjective
experience of giving a speech to a comparable real-life audience than levels elicited by a Virtual
Reality (VR) environment and (c) to determine whether the VC task elicited higher levels of
presence and fear of negative evaluation than the VR task, more closely replicating levels
elicited by an in vivo speech. All participants gave an impromptu speech under three conditions:
in vivo, VC, and VR audience while measures of physiological arousal, self-reported distress,
and presence were obtained. Results demonstrated that the VC task elicited significantly greater
increases in heart rate, electrodermal activity, and self-reported distress than the VR task and VC
responses were not significantly different from in vivo. In addition, participants reported levels
of immersion and fear of negative evaluation during the VC task that were significantly greater
than during the VR task, and did not differ significantly from in vivo. Clinical implications of
these findings including cost effectiveness and the role of VC in the treatment of SAD are
discussed.
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CHAPTER ONE: INTRODUCTION
Social Anxiety Disorder (SAD) is one of the most prevalent and impairing anxiety
disorders. With a lifetime prevalence rate of 13% among adults (Kessler, Petukhova, Sampson,
Zaslavsky, & Wittchen, 2012), SAD is characterized by a “marked fear or anxiety about one or
more social situations in which the individual is exposed to possible scrutiny by others
(American Psychiatric Association, 2013). SAD typically emerges during childhood or mid-tolate adolescence with approximately 50% developing this disorder by age 11 and almost 80% by
age 20 (Beidel, Turner, & Morris, 1999; Stein & Stein, 2008). Among the most commonly
feared situations (e.g., meeting new people, initiating and maintaining conversations, attending
parties, eating or writing in front of others, using public restrooms, and speaking up in class or at
meetings), the most ubiquitously distressing is public speaking (Mannuzza et al., 1995; Stein,
Walker, & Forde, 1996). Although most individuals fear a variety of situations, a specifier of
“performance only” is added if anxiety only occurs during performance situations (APA, 2013).
At their core, individuals with SAD are excessively fearful of doing or saying something
to elicit judgment that they are somehow inadequate or otherwise unlikeable. Exposure to feared
circumstances is often met with negative cognitions such as “Everyone will think I’m stupid,” in
addition to significant symptoms of physiological arousal (e.g., increased heart rate, sweating,
blushing, and trembling). Although considered an innate and sometimes invaluable reaction to
perceived threat, those with SAD fear these reactions will result in further scrutiny if apparent to
others (APA, 2013; Roth, Antony, & Swinson, 2001). These individuals often disregard the
possibility of alternate, benign interpretations for their behavior and in turn, are dismissive of
positive social cues (Veljaca & Rapee, 1998).
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Encounters with feared situations almost always provoke anxiety and are avoided or
otherwise tolerated with unremitting, intense distress (APA, 2013). Avoidance behaviors can be
as basic as avoiding eye contact, speaking softly, and over-preparing for a speech or as extensive
as disenrolling from college to avoid requisite public speaking classes. The literature has
consistently demonstrated associations between this pattern of distress and behavioral avoidance
with significantly reduced quality of life (Stein & Kean, 2000; Wittchen, Fuetsch, Sonntag,
Müller, & Liebowitz, 2000) and impairment in occupational, academic, social, and emotional
functioning (Acarturk, Cuijpers, Van Straten, & De Graaf, 2009; Davidson, Hughes, George, &
Blazer, 1993; Turner, Beidel, Dancu, & Keys, 1986; Wittchen & Beloch, 1996; Zhang, Ross, &
Davidson, 2004). Despite intelligence and ability, individuals with SAD are approximately 10%
less likely to obtain higher education, are over twice as likely to be unemployed, earn on average
10% less salary, and are less likely to obtain upper-level jobs than those without SAD
(Katzelnick et al., 2001; Moitra, Beard, Weisberg, & Keller, 2011; Stein & Kean, 2000).
Extensive social isolation and diminished self-esteem can contribute to the development of
comorbid conditions such as other anxiety disorders, depression, and substance use disorders
(Kessler, Stang, Wittchen, Stein, & Walters, 1999; Schneier, Johnson, Hornig, Liebowitz, &
Weissman, 1992) . These individuals are also more likely to seek health care services and take
prescription medication (Patel, Knapp, Henderson, & Baldwin, 2002). Overall, the annual cost
of anxiety disorders including SAD approximates $42.3 billion, or $1,542 per individual
(Greenberg et al., 1999).
Despite the burden placed on the individual and the economy, over 80% of individuals
with SAD are not receiving treatment (Grant et al., 2005). The most commonly identified
2

barriers include an inability to afford treatment, uncertainty, fear of negative evaluation, and
ironically, the symptoms of SAD themselves (Olfson et al., 2000). Additionally, over 75% of
counties in the United States have a paucity of mental health professionals, particularly
professionals with training in evidence-based treatments for SAD, leaving a sizeable portion of
the population without access (Goisman, Warshaw, & Keller, 1999; Thomas, Ellis, Konrad,
Holzer, & Morrissey, 2009; Wang, Berglund, & Kessler, 2000).

Current Treatments
Pharmacological Treatments
Medications such as selective serotonin reuptake inhibitors (SSRIs) and serotoninnorepinephrine reuptake inhibitors (SNRIs) are frequently prescribed for the treatment of SAD
(Blanco, Bragdon, Schneier, & Liebowitz, 2013). These newer (second-generation) drugs tend
to have large treatment effect sizes, few side effects, the strongest outcomes, the lowest dropout
rates and are recommended as the first-line pharmacological treatment for SAD (Blanco et al.,
2013; Gould, Buckminster, Pollack, Otto, & Yap, 1997; Katzelnick et al., 1995; van Vliet, den
Boer, & Westenberg, 1994). Other commonly prescribed classes of medication include
benzodiazepines which have the potential for abuse and side-effects (e.g., sedation and impaired
cognition) (Blanco et al., 2013) and β-adrenergic antagonists (β-blockers) which may only
temporarily improve the physiological effects of anxiety (Gould et al., 1997). Despite the
potential benefits of pharmacological treatments, many potential patients and psychiatrists are
deterred by side-effects, withdrawal problems, potential for relapse, and unknown teratogenic
effects in pregnant women (Fyer et al., 1987; Gould et al., 1997; Marks et al., 1993).
3

Cognitive-Behavioral Therapy
Currently, cognitive-behavioral therapy (CBT) is the most established and
recommended psychotherapeutic treatment for SAD. Although CBT treatment paradigms may
consist of multiple components (e.g., psychoeducation, exposure to feared social stimuli (EXP),
homework assignments, cognitive therapy (CT), progressive muscle relaxation (PMR), applied
relaxation, and in some cases social skills training (SST). EXP produced the best outcomes
when components are compared (Gould et al., 1997). EXP is better suited than CT in addressing
the avoidance behaviors believed to maintain and contribute to SAD by replacing maladaptive
memory structures through a mechanism known as emotional processing theory (Foa & Kozak,
1986; Gould et al., 1997).
Typically during EXP, patients confront their fears in a safe, controlled
environment by exposure to either actual (in vivo) or imagined stimuli. Through a process
known as habituation or extinction, repeated exposure to feared stimuli without negative
consequences yields a natural decrease in the physiological and cognitive aspects of the fear over
time. The patient’s worst fear is targeted either right away (flooding) or in a gradual
(hierarchical) manner. Although extant research has demonstrated that that EXP utilizing in vivo
stimuli is the most effective approach for treating SAD (Craske et al., 2008), in vivo exposures
are not always practical, ethical, or are difficult or expensive to recreate or repeat. In addition,
the stimuli may elicit such extreme fear that the patient is unwilling to enter or remain in
treatment. Although imaginal exposure may be useful in these circumstances, imaginal
exposure relies heavily on the patient’s cognitive skills and creative abilities to produce complete
immersion in the scenario and to prevent avoidance via cognitive distraction.

4

Virtual Reality Exposure Therapy
Using computer-generated graphics viewed through a head mounted display (HMD)
coupled with other sensory stimuli, virtual reality exposure therapy (VRET) was developed as a
means to overcome these limitations (Krijn, Emmelkamp, Olafsson, & Biemond, 2004;
Rothbaum & Hodges, 1999). The HMD is a visor that allows the individual to view the images
on a display screen while blocking potentially distracting stimuli from the outside environment.
The HMD utilizes an electromagnetic tracking system that displays different areas of the VRE
corresponding with changes in head movements. On a separate screen, the therapist can see the
patient’s view and manipulate the environment to increase presence by including audio and
olfactory stimuli (Krijn et al., 2004; Rothbaum & Hodges, 1999). Although data have
consistently demonstrated that VR may in fact be a useful tool for the treatment of specific
phobias and SAD, including public speaking anxiety (Anderson, Rothbaum, & Hodges, 2003;
Anderson et al., 2013; Anderson, Zimand, Hodges, & Rothbaum, 2005; Harris, Kemmerling, &
North, 2002; Klinger et al., 2005; Wiederhold & Wiederhold, 1998), methods of exposure
therapy must meet certain requirements and research examining the relationship between those
tenants and VRET is sparse.
For example, consistent with emotional processing theory (Foa & Kozak, 1986), (a) the
patient must feel immersed in the VRE as opposed to a passive observer, (b) the VRE must also
be generalizable to the corresponding real-life situation, and (c) the VRE should elicit
physiological arousal, indicating that the core elements of the fear have been activated (Lee,
2004; North et al., 2008; Regenbrecht, Schubert, & Friedmann, 1998; Schubert, Friedmann, &
Regenbrecht, 2001; Schuemie et al., 2000). Although extant research has suggested that full
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immersion with exposure stimuli may not be necessary when treating specific phobias (Podina,
Koster, Philippot, Dethier, & David, 2013), additional research is needed to elucidate the
generalizability of these findings to SAD.
Studies to date have yielded promising results, demonstrating the ability of VR
environments to elicit physiological arousal (e.g., blood pressure and heart rate), self-reported
distress, and a sense of immersion, but conclusions were limited by numerous factors (e.g.,
small sample sizes, lack of a clinical population and comparable control task) (Hartanto et al.,
2014; Kotlyar et al., 2008; Pertaub, Slater, & Barker, 2002; Slater, Pertaub, Baker, & Clark,
2006). Although one trial did demonstrate the ability of a VR conversation task to elicit
significant levels of subjective distress and immersion when compared to an in vivo task (Powers
et al., 2013), this study lacked the inclusion of a clinical population and objective measures of
anxiety, thus its relevance to the treatment of a clinical population is unclear.
In an effort to address these limitations, a trial by Owens and Beidel (2015) compared
physiological responses elicited by a VR public speaking task and a comparable in vivo speech
task in individuals with SAD and individuals with no diagnosis. This study expanded upon
physiological response data by including measurements of electrodermal activity (EDA),
respiratory sinus arrhythmia (RSA), and heart rate (HR) measured continuously before, during
and after each of the two tasks. To replicate earlier studies, these objective measures of arousal
were compared to self-report measures of anxiety as well as a measure of presence. Results
demonstrated that the VR speech task elicited significant increases in these metrics over baseline
conditions, but the VR task was less anxiety provoking than the in vivo speech task. The
findings suggest that although the VR stimuli were sufficiently similar to real-life stimuli to
6

support its utility as a tool for conducting exposure therapy, the VR was not equivalent to an in
vivo audience and may be better suited as an intermediate step in a hierarchy or as a means to
encourage those more hesitant about in vivo exposure to initiate treatment. In addition,
participants reported a moderate level of presence in the VR task, but significantly less than in
the in vivo speech task, particularly when the in vivo task was administered first. For example,
following the VR speech task, a number of participants remarked, “That wasn’t nearly as scary
as giving a speech with real people, you know the virtual people aren’t thinking negatively about
you.” These findings indicated that the VR task may not sufficiently address a primary concern
of those with SAD – fear of negative evaluation by others (Clark & Wells, 1995; Horley,
Williams, Gonsalvez, & Gordon, 2004; Rapee & Heimberg, 1997).
Although research has clearly demonstrated the superiority of in vivo exposures, in the
case of patients with SAD, the majority of clinicians do not have consistent access to volunteers
to serve as audience members for a speech or access to conference rooms/auditoriums large
enough to hold an audience. Those that do, face the time-consuming challenge of recruiting and
coordinating audience members. The advantages of using VR when in vivo exposure proves too
troublesome are many. Despite its convenience, VR environments have limitations. Aside from
the initial equipment cost (including a computer capable of running the software), there are
software licensing fees and the cost of both training staff and maintaining the system. Although
prices vary by distributor, VR software and hardware packages can cost thousands, placing this
technology out of reach of many clinicians’ budgets. Given these shortcomings, it is worthwhile
to investigate tools for conducting exposure therapy that are less elaborate and better address
fears of negative evaluation.
7

Capitalizing on the benefits of in vivo and VR exposure stimuli, while overcoming many
of the associated drawbacks, utilization of a pre-recorded audience may restore the evaluative
component lost in VREs while greatly reducing the need for costly VR equipment and
eliminating the difficulties encountered when forming in vivo public speaking exposures. Viewed
on a TV screen, a pre-recorded audience presented to participants as a live audience in a remote
location could elicit fears of negative evaluation similar to a “live” audience. The current study
sought to expand upon previous work (Owens & Beidel, 2015) by replicating the VR vs. in vivo
comparison and including a third task, in which participants are instructed to provide a speech in
front of a “representational” videoconferencing audience.

Current Study
This study has the following hypotheses:
1. Participants will experience a significant increase in physiological arousal and
self-reported distress from baseline levels during the videoconferencing speech
task.
2. Participants will have the greatest increase from baseline levels of physiological
and self-reported distress during the in vivo speech task and the least during the
VR speech task.
3. Participants will report the highest levels of presence and fear of negative
evaluation in the in vivo speech task and the least in the VR speech task.
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CHAPTER TWO: METHODOLOGY
Procedure Overview
Participants were recruited via community advertisement and through the university’s
undergraduate research pool. Participants were admitted into the study if they met diagnostic
criteria for SAD and met additional inclusion and exclusion criteria. Specifically, participants
were required to have a Clinician Severity Rating (CSR) of at least 4 on the Anxiety Disorders
Interview Schedule for the DSM-5 (ADIS-5; Brown & Barlow, 2014). Participants with
additional disorders (e.g., depression) were included if they were secondary to their primary
diagnosis of SAD. However, presence of a lifetime diagnosis of current bipolar disorder,
suicidal ideation, current alcohol or substance abuse, or psychosis was exclusionary. Further,
participants were only included if they endorsed frequently experiencing anxiety when speaking
in front of at least 5 people. Additional exclusion criteria included any unstable or serious
medical conditions or taking any medications that, in the opinion of the researcher, might have
interfered with the measures being assessed (e.g., psychoactive medications, anti-hypertensives).
Forty-eight (48) adults responded to recruitment efforts. Five participants met exclusion
criteria for comorbid disorders: (2) primary Major Depressive Disorder, (1) primary Generalized
Anxiety Disorder, (1) Alcohol Use Disorder, (1) Bipolar Disorder with Psychotic Features.
Seven participants did not meet the minimum CSR requirement for study inclusion (e.g., subclinical SAD) and one participant did not meet criteria for any diagnosis. An additional 2
participants were removed due to incomplete physiological assessment data. Finally, 3
participants were removed as their HR and SCR data were determined to be outliers, as the
values fell above the 3rd quartile. The final sample consisted of 30 adults with SAD (14 males;
9

16 females) ranging in ages from 18 to 42 years (M=21.37). The sample was ethnically varied
consisting of 40% Caucasians, 23% African Americans, 20% Hispanics/Latinos, 13% Asian
American/Pacific Islanders, and 3% who identified as belonging to the Other category (e.g., of
mixed ethnic background). Demographic characteristics, comorbid diagnoses, and clinical
severity scores are displayed in Table 1. Two of the participants were currently receiving talk
therapy to address anxiety and depression related concerns; however, none of the participants
reported prior experience with exposure therapy.

Table 1 Demographic and Clinical Severity Data
Variable
Age M(SD)

.

SAD (N=30)
21.37(5.49)

Gender
Males

14

Females

16

Race/Ethnicity
Caucasian

12

African American/Black

7

Hispanic/Latino

6

Asian/Pacific Islander

4

Other

1

Assessment Measures
ADIS-5 SAD CSR

M(SD)
5.60(1.19)

SPAI Difference Score

95.55(19.78)

HAMD Total Score

12.57(6.41)

Comorbidity

(N)

10

Variable

.

SAD (N=30)

MDD

2

Specific Phobia

4

GAD

4

PTSD

1

Unspecified Feeding/Eating

1

ADIS-5 SAD CSR=Anxiety Disorders Interview Schedule for the DSM-V Social Anxiety Disorder Clinician
Severity Rating, SPAI=Social Phobia and Anxiety Inventory, HAMD=Hamilton Depression Scale, MDD=Major
Depressive Disorder, PTSD=Post-Traumatic Stress Disorder, GAD=Generalized Anxiety Disorder

Diagnostic Measures
Diagnostic Interview
Following the consent process, potential participants were administered the Anxiety and
Related Disorders Interview Schedule for the DSM-5 – Adult Version (ADIS-5L; Brown &
Barlow, 2014). As part of the ADIS-5, a Clinician Severity Rating (CSR) was assigned to each
diagnosis, using a 9-point scale (0-8) where higher numbers are indicative of greater severity.
The ADIS-5 was conducted by the first author, a doctoral student at UCF. To calculate interrater reliability and agreement, twenty-percent of the interviews were scored by a second blinded
evaluator (e.g., a doctoral student within the clinical psychology program). For the diagnosis of
SAD, the kappa coefficient was k=1.00. Inter-rater agreements for the CSR intraclass correlation
coefficient was ICC(3,2)= 1.00 and the reliability was r=1.00.
In addition to the diagnostic interview, the following measures were included to
determine study eligibility and SAD symptom severity:
Participants completed the Social Phobia and Anxiety Inventory (SPAI; Turner, Beidel,
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Dancu, & Stanley, 1989) to assess the range and severity of their social fears. The SPAI is a 45
item self-report questionnaire measuring the somatic, cognitive, and behavioral aspects of social
phobia. The SPAI consists of 2 subscales, social phobia and agoraphobia. The SPAI total score
is calculated as the difference between two subscales, providing a more pure measure of social
phobia. The SPAI has high test-retest reliability of .86 and differentiates patients with social
phobia from normal controls or from patients with other anxiety disorders (Turner et al., 1989).
In addition, the SPAI has good concurrent and external validity (Beidel, Turner, Stanley, &
Dancu, 1989; Turner et al., 1989).
To assess potential depressive symptoms and rule out participants who may be suffering
from significant depression, the first author administered the 21-item Hamilton Rating Scale for
Depression (HAM-D; Hamilton, 1960). To calculate inter-rater reliability and agreement,
twenty-percent of the interviews were scored by a second blinded evaluator (e.g., a doctoral
student within the clinical psychology program). Inter-rater agreement for the HAM-D was
ICC(3,2)=.996 and the reliability was r=.990. With mean scores ranging from 3-27 and with
depressive symptoms presenting as secondary to SAD, no participants were excluded from the
current study based on their HAM-D scores.

Outcome Measures
Participants completed the following battery of self-report measures:
The Self-Statements During Public Speaking (SSPS; Hofmann & DiBartolo, 2000) is a
10-item questionnaire designed to assess fearful thoughts experienced during public speaking.
The SSPS consists of two 5-item subscales, the “Positive Self-Statements” (SSPS-P) and the
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“Negative Self-Statements” subscale (SSPS-N). The SSPS has demonstrated acceptable levels
of internal consistency and test-retest reliability and differentiates high and low levels of public
speaking anxiety (Hofmann & DiBartolo, 2000).
The Brief Fear of Negative Evaluation-II (BFNE-II; Carleton, McCreary, Norton, &
Asmundson, 2006) is a revised version of the Brief Fear of Negative Evaluation Scale (BFNE;
Leary, 1983). This 12-item scale provides a measurement of worry and distress encountered
upon the possibility of negative evaluation or judgment by others. Each item is rated on a 5point Likert scale between 1 and 4 with higher scores indicating greater fear. This measure has
demonstrated good confirmatory single-factor fit and a moderate degree of convergent and
discriminate validity with other measures of social anxiety (Carleton, Collimore, & Asmundson,
2007). A total score of 38 is considered the clinical cut-off for differentiating between those
with and without SAD (Carleton, Collimore, McCabe, & Antony, 2011). For the purposes of the
current study, a modified version was administered following each speech task, referencing the
fear of negative evaluation elicited by the task, rather than across all situations.
The Subjective Units of Distress Scale (SUDS) asked the participant to rate their own
level of anxiety using a 9-point likert type rating scale (0 to 8; no distress to extreme distress).
Two Visual Analogue Scales (VAS) were administered after each speech task to assess
the degree to which the participant felt engaged/involved with the speech task environment and
separately, how strong was their sense of “being there.” Participants were asked to indicate their
response by drawing a vertical mark on a 100mm line, which is anchored by labels representing
the extremes of the continuum (e.g., Not Engaged/Involved At All to Complete
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Engaged/Involved and Completely Detached/No Sense of Being There to Complete Sense of
“Being There”).

Behavioral Measures
The behavioral assessment consisted of (a) an impromptu speech in front of a live 5person audience, (b) an impromptu speech in front of a 5-person virtual audience, and (c) an
impromptu speech in front of a 5-person “representational” videoconferencing audience. The
VR speech task utilized the conference room environment from Virtually Better’s© software
package. In this VRE, the participant viewed a waiting room through a HMD and the researcher
guided the participant into a virtual conference room in which a five person audience was seated
around a conference table. The audience members consisted of two men and three females of
varying ethnicities (3 Caucasians, 1 African American, and 1 Asian) wearing business casual
attire.
For the in vivo speech task, the virtual conference room was recreated in a conference
room in UCF’s Psychology Clinic. Four to five undergraduate volunteers, instructed to wear
business casual attire, were seated around a conference table, consistent with the virtual task.
Participants were told the audience members would not be interacting with them.
The videoconferencing task recreated the virtual conference room by utilizing a prerecorded audience, consisting of five volunteers wearing business casual attire, seated around a
conference table. Participants viewed this recording on a 32” flat screen TV (from a distance of
approximately 5ft away) and were told the recording was actually a live-audience in a remote
location, being viewed through videoconferencing software. Participants were told that the
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audience was able to view their performance through a webcam but would not be interacting
with them.

Physiological Measures
During the behavioral assessment, HR and EDA were continuously monitored and
recorded using the locally monitored MindWare Mobile Impedance Cardiograph system.
Continuous recording allowed for the assessment of physiological arousal over time and in
relation to the three speech tasks. MindWare Version 3.1 allowed for the conversion of
physiological data into meaningful statistical data to be analyzed using MindWare analysis
software version 3.1. HR, a measure of sympathetic and parasympathetic responses to external
stimuli was measured via EKG at 30 second intervals. EDA, as measured by skin conductance
level (SCL) and response (SCR) provided measures of sympathetic activity of the autonomic
nervous system (ANS) and was recorded continuously.

Cost-Effectiveness Measures
Approximate clinician labor cost for conducting an in vivo exposure session was
determined by recording the approximate time the researcher spent performing recruitment tasks
for audience volunteers and multiplied by the average hourly wage for a private practice clinician
($150/hr). Clinician time for conducting an exposure session with each tool was not included as
this is expected to be consistent across the three conditions. An expert in the field of virtual
reality software development, Josh Spitalnick, Ph.D., provided the average costs to develop a
virtual reality speech environment (e.g., audience member recruitment, voiceovers, animation,
and programming) and the approximate cost to the clinician in terms of hardware and software
15

expenses (personal communication, April 20th, 2015). Similarly, an expert in film production,
Scott Elias, was consulted for approximate personnel costs to develop the videoconferencing task
environment (personal communication, April 24th, 2015). An estimate for clinician costs in
terms of hardware was calculated based on current retail prices.

Procedure
Eligible participants were fitted with (2) 1 ½”x 1” disposable foam electrodes containing
0% Chloride wet gel on the palm of the participant’s non-dominant hand, (3) 1 ½” disposable
foam electrodes containing 7% Chloride wet gel on the participant’s torso, and a respiration belt.
The electrodes were connected to a mobile recording device that each participant wore on the
waistband of his/her pants. Participants were asked to sit quietly during a 10-minute
adaptation/baseline period. At the conclusion of the baseline period, participants provided a
SUDS rating and were informed that they would participate in three 5-minute speech tasks.
Participants were provided with 5 topics (a different set of 5 topics was provided for each task
with topic areas including: qualities of a good president, whether school uniforms should be
required, the influence of television on children, and the legal drinking age) and were instructed
to choose up to 3 topics to use during their first speech. Participants were given 3 minutes to
prepare this speech and were allowed to reference their topic cards during the task, but not any
notes made during the preparation period. After delivering their speech, participants recorded
their SUDS rating and completed the SSPS, VAS, and BFNE-II. The participant then sat quietly
for 5 minutes before the next task to allow the participant’s physiological response to return to
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approximately baseline levels. Participants were then provided with a new set of 5 topics and
then the same procedure was repeated for the second and third speech tasks.

Study Design
This study used a within-subjects design (Condition: In Vivo, Virtual Realty, and
Videoconferencing). To control for order effects and other potential sources of bias, the order of
task administration was counterbalanced using a Latin square design in which participants were
randomly assigned to one of six different task order combinations. Measures of HR, SCL, SCR,
were recorded continuously before and during each task and SUDS ratings were obtained at the
end of baseline and each experimental task. Measures of cognitive distortions (SSPS), fear of
negative evaluation (BFNE-II), and presence (VAS) were also obtained after each experimental
task.

Analytical Strategy
SCRs were counted if the fluctuation exceeded .05µS. HR data were edited for artifact
following data collection. The mean of the final 60 seconds of the initial baseline period was
used in the calculation of change scores. The mean change score of HR and SCL for each 5minute speech were calculated and used as the overall task mean change score. The mean
number of SCRs was calculated and used as the overall task mean.
One-tailed, paired samples t-tests were used to examine the ability of the
videoconferencing speech task to elicit a significant increase in physiological arousal over
baseline. A series of 3x6 Mixed Subjects Repeated Measures ANOVAs with planned
comparisons of task effects were used to analyze physiological arousal (e.g., HR, SCL, and
17

SCR), self-reported distress (e.g., SUDS), self-reported perception of task performance (e.g.,
SSPS), self-reported fear of negative evaluation (e.g., BFNE-II) and degree of engagement with
the task environments (e.g.,VAS). A variable representing task order assignment was included
as a between-subjects factor to assess for the presence of order effects. Significant F scores for
this between-subjects factor were followed up by Bonferroni corrected t-tests to determine where
differences occurred.
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CHAPTER THREE: FINDINGS
Does the VC Speech Task Produce Feelings of Immersion?
Prior to determining whether the VC speech task elicited physiological arousal and
subjective distress, VAS “Engagement” and “Being There” scores were analyzed to determine
whether the VC task was a valid manipulation. There were no significant main or interaction
effects on the VAS Engagement scale suggesting similar engagement in the VC (M(SD)=
60.92(27.74)), in vivo (M(SD)=58.58(34.78)), and VR (M(SD)=55.33(27.62)) speech tasks. In
contrast, there was a significant main effect for task on the VAS “Being There” scale
(F(2,48)=5.656, p=.006). Participants had a significantly stronger sense of “being there” during
the in vivo (M(SD)= 61.25(36.41)) and VC (M(SD)=60.22(30.76)) tasks than during the VR task
(M(SD)=45.32(28.51)). The in vivo and VC task ratings were not significantly different. The
main effect for order and interaction effects were not significant. RMANOVA results and scores
for each task are depicted in Table 2.

Does the VC Speech Task Elicit More Cognitive Distortions, Fear of Negative Evaluation, and
Subjective Distress than an Equivalent VR Speech Task?
On the SSPS Positive subscale, there were no main or interaction effects; all tasks elicited
similar positive self-statements (M(SD)Vivo=13.13(3.45); M(SD)VR=13.87(2.83);
M(SD)VC=13.23(3.52)). Although there was a significant main effect for task order
(F(5,24)=3.578, p=.015), none of the follow-up pairwise comparisons were significant.
Additionally, there were no significant main effects or interactions for the SSPS Negative
subscale; all task elicited a similar degree of cognitive distortions (M(SD)Vivo=13.33(3.18);
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M(SD)VR=12.93(2.79); M(SD)VC=13.97(3.20)). RMANOVA results and scores for each task for
both scales are depicted in Table 2.
There were significant interactions for both the BFNE-II and SUDS measures (see Task
Order Effects). Although main effects are not typically interpreted in presence of a significant
interaction, for the goals of the current study results of the significant main effect for Task are
important and as follows: With regard to the BFNE-II, Mauchly’s test indicated that the
assumption of sphericity had been violated, χ2(2)=13.74, p=.001, therefore degrees of freedom
were corrected using Greenhouse-Geisser estimates of sphericity (ɛ=.69). There was a significant
main effect for task type on the BFNE-II Total Score (F(1.379,33.107)=39.015, p<.001).
Participants reported a stronger fear of negative evaluation during the in vivo
(M(SD)=49.33(6.90)) and VC speech tasks (M(SD)=47.83(8.47)) than during the VR speech
task (M(SD)=33.73(15.96)). The in vivo and VC ratings were not significantly different.
Similarly, the main effect for task type on the SUDS (change over baseline) was significant
(F(2,48)=33.891, p=<.001) with participants reporting more subjective distress during the in vivo
(M(SD)=4.47(2.05)) and VC speech tasks (M(SD)=4.43(1.99)) than during the VR speech task
(M(SD)=2.50(2.06)). The in vivo and VC ratings were not significantly different. RMANOVA
results and scores for each of these tasks are depicted in Table 2. Simple effects associated with
the significant interactions are discussed below.
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Table 2: RMANOVA Results and Descriptive Statistics for Measures of Self-Reported
Distress
M(SD)
Partial
Variable

In Vivo

VR

VC

F

p

η2

SUDS (Change Score)
Main Effect: Task 4.47(2.05)a
2.50(2.06)b
4.43(1.99)a
33.891
<.001
Main Effect: Order
.175
.969
TxO Interaction
5.650
<.001
BFNE-II Total
Main Effect: Task 49.33(6.90)a
33.73(15.96)b 47.83(8.47)a
39.015
<.001
Main Effect: Order
9.638
<.001
TxO Interaction
2.905
.018
VAS “Engagement”
Main Effect: Task 58.58(34.78)
55.33(27.62)
60.92(27.74)
.803
.454
Main Effect: Order
.982
.449
TxO Interaction
1.921
.065
VAS “Being There”
Main Effect: Task 61.25(36.41)a 45.32(28.51)b 60.22(30.76)a 5.656
.006
Main Effect: Order
.816
.550
TxO Interaction
1.561
.148
SSPS Positive Subscale
Main Effect: Task 13.13(3.45)
13.87(2.83)
13.23(3.52)
1.320
.277
Main Effect: Order
3.578
.015
TxO Interaction
1.112
.373
SSPS Negative Subscale
Main Effect: Task 13.33(3.18)
12.93(2.79)
13.97(3.20)
2.380
.103
Main Effect: Order
.084
.994
TxO Interaction
1.542
.154
SUDS=Subjective Units of Distress Scale, VAS=Visual Analogue Scale, SPSS=Self Statements about Public
Speaking Questionnaire, BFNE-II=Brief Fear of Negative Evaluation-II
Means not sharing superscripts are significantly different at p<.05

.585
.035
.541
.619
.668
.377
.032
.170
.286
.191
.145
.245
.052
.427
.188
.090
.017
.243

Task Order Effects.
To follow-up on the significant interactions for the BFNE-II (F(6.897, 33.107)=2.905,
p=.018) and SUDS (F(10,48)=5.650, p<.001) scales, Bonferroni corrected tests of simple effects
revealed that unless presented first, VR elicited less self-reported distress (SUDS) and fear of
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negative evaluation (BFNE-II) than the in vivo and VC exposure tasks. Findings are detailed in
Tables 3 and 4 below.

Table 3: Simple Effects for the BFNE-II Total Score
Speech Task
M(SD)
Task Order

In Vivo

VR

VC

VR:Vivo:VC
VR:VC:Vivo
Vivo:VC:VR
Vivo:VR:VC
VC:Vivo:VR
VC:VR:Vivo

53.40(6.54)a
53.20(4.32)a
42.20(6.50)a
50.40(6.50)a
49.00(8.15)a
47.80(5.07)a

46.40(11.15)a
54.00(5.29)a
23.80(11.10)b
21.60(12.36)b
31.40(13.99)b
25.20(10.18)b

54.80(4.97)a
54.20(5.12)a
39.40(5.77)a
43.80(10.66)a
51.60(4.72)a
43.20(5.85)a

Means not sharing superscripts are significantly different at p<.05

Table 4: Simple Effects for SUDS Change Score
Speech Task
M(SD)
Task Order

In Vivo

VR

VC

VR:Vivo:VC
VR:VC:Vivo
Vivo:VC:VR
Vivo:VR:VC
VC:Vivo:VR
VC:VR:Vivo

4.80(1.48)a
3.00(3.61)a
5.80(1.30)a
5.60(1.95)a
4.00(.71)a
3.60(1.14)a

4.00(1.22)a
4.00(3.08)a
1.80(.84)b
2.00(2.12)b
1.80(1.64)b
1.40(1.82)b

4.00(2.24)a
4.20(2.59)a
4.00(1.22)c
4.40(2.61)a
5.20(1.92)a
4.80(1.92)a

Means not sharing superscripts are significantly different at p<.05
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Does the VC Speech Task Elicit Physiological Arousal and Subjective Distress?
Participation in the VC speech task produced a significant HR increase of 16.68bpm from
baseline (M(SD)=75.29(10.09) vs. VC task (M(SD)=91.97(10.79); t(29)=-17.48, p<.001).
Participants also had a significant SCL increase of 6.55µS during the VC speech task over
baseline (M(SD)=5.38(5.63) vs. VC task M(SD)=11.93(6.82); t(29)=-11.06, p<.001). Finally,
participants had significantly more SCRs during the VC speech task (M(SD)=6.82(3.19)) than
during baseline (M(SD)=3.07(4.06); t(29)=-5.23, p<.001). With regard to the ability of the VC
task to elicit subjective distress, participation in the VC task produced a significant increase in
SUDS scores of 4.43 when compared to baseline levels (M(SD)=1.67(1.84) vs. VC task
(M(SD)=6.10(1.60); t(29)=-12.17, p<.001), producing a high level of subjective distress.

Does the VC Speech Task Produce a Greater Increase in Physiological Arousal than an
Equivalent VR Speech Task?
The main effect for task type on HR was significant (F(2,48)=7.847, p=.001) with
participants exhibiting significantly greater increases in HR during the in vivo
(M(SD)=16.03(6.61)) and VC speech tasks (M(SD)=16.68(5.23)) than during the VR speech task
(M(SD)=13.86(5.65)); however, there was no significant difference between the in vivo and VC
conditions. There was no significant interaction or main effect for task order. RMANOVA
results and scores for each task are depicted in Table 5.
The main effect for task type on SCL was significant (F(2,48)=9.610, p<.001).
Participants exhibited an increase in SCL over baseline during the in vivo (M(SD)=6.29(3.01))
and VC speech tasks (M(SD)=6.55(3.25)), but they were not significantly different. Further,
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there was a significantly greater change in SCL from baseline during the in vivo and VC speech
tasks than during the VR speech task (M(SD)=5.39(3.04)). There was no significant interaction
or main effect for task order. RMANOVA results and scores for each task are depicted in Table
5.
The main effect for task type on SCR was significant (F(2,48)=14.290, p<.001) with all
participants exhibiting more SCRs during the in vivo (M(SD)=6.87(3.28)) and VC speech tasks
(M(SD)=6.82(3.19)) than during the VR speech task (M(SD)=5.04(3.02)). The frequency of
SCRs elicited during the in vivo and VR speech tasks was not significantly different. There was
no significant interaction or main effect for task order. Scores for each task are depicted in Table
5.

Table 5: RMANOVA Results and Descriptive Statistics for Physiological Measures
M(SD)
Partial
Variable

In Vivo

VR

VC

F

HR (Change Score)
Main Effect: Task 16.03(6.61)a
13.86(5.65)b 16.68(5.23)a 7.847
Main Effect: Order
.228
TxO Interaction
1.298
SCL (Change Score)
Main Effect: Task 6.29(3.01)a
5.39(3.04)b
6.55(3.25)a
9.610
Main Effect: Order
1.370
TxO Interaction
1.124
SCR (Mean Total)
Main Effect: Task 6.87(3.28)a
5.04(3.02)b
6.82(3.19)a
14.290
Main Effect: Order
.565
TxO Interaction
.901
HR=Heart Rate, SCL=Skin Conductance Level, SCR=Skin Conductance Response
Means not sharing superscripts are significantly different at p<.05

24

p

η2

.001
.947
.258

.246
.045
.213

<.001
.270
.364

.286
.222
.190

<.001
.726
.539

.373
.105
.158

Is the VC Speech Task More Cost Effective than VR?
In Vivo Task Costs
Assuming that clinic space and office furniture (e.g., table and 5 chairs) is readily
available and free for usage (as in this investigation), the primary costs for conducting the in vivo
speech task involve costs for the clinician’s time to recruit, train, schedule, and manage speech
task volunteers. Utilizing an average rate of $150/hr for the typical private practice clinician, the
costs for arranging an in vivo speech session are estimated to be as follows:
-

Volunteer recruitment and training
o 8 hours of clinician labor (e.g., Advertising for volunteers, reading through
volunteer applications, multiple emails with applicants, training, and setting up
lab access) = $1,200

-

Scheduling and Coordinating Volunteers for Each Task
o 30 minutes of clinician labor per session (e.g., sending 1-2 email requests to list of
volunteers for sign-ups, finding additional staff to supplement audience,
responding to volunteer questions and scheduling concerns) = $75/session

-

Total estimated cost for 30 in vivo speech task exposure sessions = $3,450

VR Task Costs
-

Estimated cost of software development (e.g., audience member recruitment, voiceovers,
animation, and programming) = $40,000-$50,000 (J. Spitalnick; personal
communication, April 20th, 2015).
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-

Estimated cost of purchasing software and necessary hardware for clinic usage = $10,000
(J. Spitalnick; personal communication, April 20th, 2015).

-

Total estimated cost for VR = $50,000-$60,000

VC Task Costs
-

Approximately 5 hours to film speech task and recruit actors
o Union videographer rate = $100/hr + Fringe benefits (26pprox.. 35%)


Total Estimated Cost = $675 (S. Elias; personal communication, April
24th, 2015)

-

Approximately 3 hours of video editing
o Union editor rate = $55/hr + Fringe benefits (26pprox.. 44%)


Total Estimated Cost = $238 (S. Elias; personal communication, April
24th, 2015)

-

Five actors to film
o SAG Extra rate = $150/day per person


-

Total Cost = $750 (S. Elias; personal communication, April 24th, 2015)

Hardware costs to run VC speech task video (e.g., laptop with HDMI port, separate
computer monitor or TV screen with HDMI port, webcam, headset, microphone)
o Estimated $600-$800 (varies widely)

-

Total estimated cost for VC = $2,263-$2,463
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CHAPTER FOUR: DISCUSSION
The current study sought to determine whether VC is a closer approximation of a
comparable in vivo speech task than VR in terms of its ability to elicit physiological arousal,
subjective distress, presence, and fear of negative evaluation in adults with SAD. Physiological
data, self-report measures of anxiety as well as a measure of presence were examined. Findings
indicated that the VC speech task elicited feelings of immersion and a significant increase in
physiological arousal and subjective distress over baseline resting conditions, outperforming the
VR task on the majority of variables assessed (VAS “Being There”, SUDS, BFNE-II, HR, SCL,
and SCR). Further, the effect elicited by the VC task was statistically equivalent to an actual
audience. Taken together, these results suggest that statistically, the VC speech task shares more
similarities to a real-life audience than the VR speech task environment.
Consistent with the findings of Owens and Beidel (2015) and similar to the findings of
Powers et al. (2013), participants described the VR speech task as less realistic and reported a
significantly diminished fear of negative evaluation during the VR task that was not attenuated
during the VC task. Following the conclusion of study procedures, over half of participants were
informally noted to say some variation of “The VR task was the easiest because the audience
wasn’t real and couldn’t judge me” (see APPENDIX B: POST-PARTICIPATION
PARTICIPANT COMMENTS). Only three participants described the VR task as the most
anxiety provoking and in each of these cases, the VR task was the first task administered. This
finding is in line with the work of Vossel and Laux (1978), which demonstrates the protective
ability of a prior stressful experience on subsequent novel experiences, an effect not shown to
occur when less stressful tasks are encountered first. All participants believed they were video27

conferencing with a live audience and a few were noted to have said, “That wouldn’t have been
as bad if I had known it was pre-recorded.” As the VR task utilized an audience with neutral
facial expressions, the degree of immersion, realism, and fear of negative evaluation may be
increased if the facial expressions were negative or varied in response to the participant. This
hypothesis is supported by the work of Pertaub, Slater, and Barker (2002) comparing positive,
neutral, and negative virtual audiences which demonstrated that regardless of the participants’
level of fear, all experienced more anxiety when giving a speech in front of the negative
audience.
Although statistically, these results may seem to indicate that the VC task is an equivalent
replacement for an actual audience, participant comments suggest that that the in vivo speech
task was the most anxiety provoking. Participants informally indicated that removing the barrier
of a TV screen and having the audience in the room induced more anxiety as it enhanced their
feelings of being the center of attention and decreased their perceived ability to escape
(APPENDIX B: POST-PARTICIPATION PARTICIPANT COMMENTS). This may be
indicative of a subtle difference between the tasks, untapped by the current outcome measures.
For example, the aforementioned participant comment may reflect a decrease in perceived
control, an unmeasured construct associated with increased distress (Mineka & Kihlstrom, 1978;
Rachman, 1978).
These results do, however, suggest that not only is the VC speech task a more face valid
tool for conducting exposure therapy than the VR task in terms of its ability to replicate the
physiological and emotional experience of giving a speech to a real-life audience, but it is vastly
more cost effective. At an estimated cost of $2,263-$2,463, the VC task is a small fraction of the
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cost of the VR system’s estimated $50,000-$60,000. Not only does the VC task cost
substantially less to develop (approximately $1,663 vs. $40,000-$50,000 for VR), but the
technology required is less advanced, significantly reducing the cost to the clinician. Using
equipment likely already at the clinician’s disposal such as a laptop and a simple TV or computer
monitor to display the video, the VC task does not require the purchase and maintenance of
specialized equipment such as a HMD. Although the primary argument for utilizing an HMD is
the need for immersion, the VC task produced a significantly greater sense of immersion,
anxious arousal, and distress without an HMD than was experienced during the VR task. In
support of these findings, extant research suggests an HMD may no longer be necessary.
Specifically, an investigation indicated that a researcher-controlled avatar projected on a screen
elicited equal distress as when projected through an HMD (Morina, Brinkman, Hartanto, &
Emmelkamp, 2014). In addition, researchers have discovered that full immersion may not be
needed to achieve the desired outcome (Feinhofer et al., 2014; Podina et al., 2013).
Over time, the VC task is more affordable than the cost of conducting in vivo exposure.
At an average cost of $150/hr, it is not only costly for a clinician to organize an in vivo exposure
session, but it is also challenging. The largest obstacle a clinician must overcome to create a
realistic public speaking exposure is to form a proper audience. Most community clinicians do
not have easy access to numerous quantities of undergraduate psychology majors seeking
research experience available to call upon when an audience is needed (as in the university
setting of the current study). While some may forge an arrangement with a nearby college or
other staff members, recruiting reliable volunteers, providing training, and organizing schedules
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can be a burdensome task. Long-term, the costs of in vivo exposure may even exceed the cost of
the VR task.
Replicating the findings of similar studies (Hartanto et al., 2014; Kotlyar et al., 2008;
Owens & Beidel, 2015; Pertaub et al., 2002; Powers et al., 2013; Slater et al., 2006), the VR task
does still elicit subjective distress, physiological arousal, and some fear of negative evaluation
but, with the exception of cognitive distortions in which values were equivalent to those of
socially anxious participants in other tasks (Hofmann & DiBartolo, 2000), to a much attenuated
degree than in the VC and in vivo speech tasks. As previous research has supported the utility of
VR exposure for treating specific phobias and SAD, including public speaking anxiety
(Anderson et al., 2003; Anderson et al., 2013; Anderson et al., 2005; Harris et al., 2002; Klinger
et al., 2005; Wiederhold & Wiederhold, 1998), these findings emphasize the role of VR as an
intermediate step on a hierarchy, as a way to ease those who are otherwise reluctant to engage in
in vivo exposure (Garcia-Palacios, Botella, Hoffman, & Fabregat, 2007), and for those who have
difficulty with imaginal exposure exercises. Given the cost of the VR equipment, future research
comparing impact of the VC speech task when participants know it is a pre-recording to the VR
environment may further help to alleviate clinician burden and remove issues related to
deception.
This study was not without limitations. Although physiological measurements are
considered to be objective measures of arousal, they can be influenced by many factors. For
example, changes in HR are found to occur just by the act of speaking (Tardy, Thompson, &
Allen, 1989), in addition the greater freedom of movement during the in vivo and VC speech
tasks than during the VR task may also have influenced HR. Furthermore, the physiological,
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behavioral, and cognitive components of Lang’s (1970) conceptualization of fear are largely
considered to function independently of one another and at different rates, making interpretation
challenging (Cox, Hallam, O’connor, & Rachman, 1983; Rachman, 1978). Lastly, when
comparing the current sample to the treatment-seeking community sample in a study by Beidel et
al. (2010), participants in the current study reported a lower average SUDS rating at baseline
(M(SD)=1.67(1.84) vs. M(SD)=3.20(1.80), respectively) and following the in vivo speech task
(M(SD)=6.13(1.48) vs. M(SD)=7.00(1.60), respectively). In addition, participants with SAD in
the current study reported a lower average SPAI score than the mean SPAI score of participants
from the treatment-seeking sample (M=95.55 vs. M=109.0, respectively). As the current sample
was less severe, these differences may affect the ability to replicate findings with treatmentseeking community samples.
In summary, this is the first investigation to use multiple measures of physiology to
examine autonomic arousal elicited by an in vivo speech task to comparable “representational”
videoconferencing and virtual reality speech tasks. Results indicated that the VC speech task
audience elicited a degree of physiological arousal, self-reported distress, and fear of negative
evaluation that was greater than a VR speech task and statistically equivalent to an in vivo
speech. The VC speech task is also much more cost-effective than the VR speech task and more
cost-effective and efficient over time when compared to the resources needed to recruit a live
audience, the difficulty of which varies widely depending on access to sources of volunteers
(e.g., undergraduate psychology students, other staff). Therefore, it appears the VC task may
potentially alleviate the burden that SAD exposure therapy places on the individual and the
clinician but may still not be a perfect substitution for giving a speech in front of a live audience.
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APPENDIX A: IRB APPROVAL LETTER
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APPENDIX B: POST-PARTICIPATION PARTICIPANT COMMENTS
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Table 6: Post-Participation Participant Comments
Number of Responses

Participant Comments

In Vivo Speech Task
15 This task was the worst/most difficult/most anxiety provoking
7 More anxiety provoking to have audience in the room
1 Easier than VC because audience seemed more like peers
2 Easier since had practice from VC and VR tasks
VC Speech Task
5 This task was the worst/most difficult/most anxiety provoking
15 Not as bad as In Vivo task but worse than VR task
3 Harder than In Vivo because audience seemed older/more authoritative
1 Just as bad as giving a speech in front of the In Vivo audience
1 Wouldn’t have been as bad if had known it was pre-recorded
1 Felt more comfortable with VC task than VR
2 Would have been more anxiety provoking if audience made eye-contact
30 Believed it was a live videoconference
VR Speech Task
3 This task was the worst/most difficult/most anxiety provoking
20 The VR Task was the easiest because the audience wasn’t real and couldn’t
judge them
2 Headset was distracting/uncomfortable
1 “They aren’t real, are they?”
1 Felt more like a video game
1 Would have been easier if not the first task
Other
1 All tasks were equally hard
4 Whether it was hard depended more on how much I knew about the
topics/Level of preparation
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